JP2001504113A - ファクターXaを阻害する複素環式化合物誘導体 - Google Patents
ファクターXaを阻害する複素環式化合物誘導体Info
- Publication number
- JP2001504113A JP2001504113A JP52227498A JP52227498A JP2001504113A JP 2001504113 A JP2001504113 A JP 2001504113A JP 52227498 A JP52227498 A JP 52227498A JP 52227498 A JP52227498 A JP 52227498A JP 2001504113 A JP2001504113 A JP 2001504113A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- group
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式(I): A−B−X1−T1(R2)−L1−T2(R3)−X2−Q (I) [式中、 Aは場合により、ハロ、オキソ、カルボキシ、トリフルオロメチル、シアノ、 アミノ、ヒドロキシ、トロ、C1〜C4アルキル(例えばメチル又はエチル)、C1 〜C4アルコキシ(例えばメトキシ又はエトキシ)、C1〜C4アルコキシカルボ ニル、C1〜C4アルキルアミノ(例えばメチルアミノ又はエチルアミノ)又はジ −C1〜C4アルキルアミノ(例えばジメチルアミノ又はジエチルアミノ)から選 択される1、2又は3個の原子又は基により置換された5員又は6員の芳香環を 表し、この環は窒素原子、酸素原子及び硫黄原子から選択される1、2又は3個 の環ヘテロ原子を含有し; Bは場合により、ハロ、トリフルオロメチル、トリフルオロメトキシ、シアノ、 ニトロ、C1〜C4アルキル、C2〜C4アルケニル及びC2〜C4アルキニルから、 置換基−(CH2)nY1[その際、nは〜4を表し、Y1はヒドロキシ、アミノ、 カルボキシ、C1〜C4アルコキシ、C2〜C4アルケニルオキシ、C2〜C4アルキ ニルオキシ、C1〜C4アルキルアミノ、ジ−C1〜C4アルキルアミノ、ピロリジ ン− 1−イル、ピペリジノ、モルホリノ、チオモルホリノ、1−オキソチオモルホリ ノ、1,1−ジオキソチオモルホリノ、ピペラジン−1−イル、4−C1〜C4ア ルキルピペラジン−1−イル、C1〜C4アルキルチオ、C1〜C4アルキルスルフ ィニル、C1〜C4アルキルスルホニル、C2〜C4アルカノイルアミノ、ベンズア ミド、C1〜C4アルキルスルホンアミド及びフェニルスルホンアミドから選択さ れる]から、置換基−(CH2)nY2[その際、nは0〜4であり、Y2はカルボ キシ、カルバモィル、C1〜C4アルコキシカルボニル、N−C1〜C4アルキルカ ルバモイル、N,N−ジ−C1〜C4アルキルカルバモイル、ピロリジン−1−イ ルカルボニル、ピペリジノカルボニル、モルホリノカルボニル、チオモルホリノ カルボニル、1−オキソチオモルホリノカルボニル、1,1−ジオキソチオモル ホリノカルボニル、ピペラジン−1−イルカルボニル、4−C1〜C4アルキルピ ペラジン−1−イルカルボニル、C1〜C4アルキルスルホンアミドカルボニル、 フェニルスルホンアミドカルボニル及びベンジルスルホンアミドカルボニルから 選択される]から、式−X3−L2−Y2[式中、X3は式CON(R5)、CON (L2−Y2)、C(R5)2O、O、N(R5)又はN(L2−Y2)を表し、L2は C1〜C4アルキレンを表し、Y2は無関係に前記したものを表し、 各R5は無関係に水素又はC1〜C4アルキルを表す]の置換基から、及び式−X3 −L3−Y1[X3は式CON(R5)、CON(L3−Y1)、C(R5)2O、O、 N(R5)又はN(L3−Y1)の基を表し、L3はC2〜C4アルキレンを表し、Y1 は無関係に前記したものを表し、各R5は無関係に水素又はC1〜C4アルキルを 表す]の置換基から選択される1又は2個の置換基により置換されたフェニレン 環を表し、かつその際、Bの置換基中の全ての複素環式基は場合により、カルボ キシ、カルバモイル、C1〜C4アルキル、C1〜C4アルコキシカルボニル、N− C1〜C4アルキルカルバモイル及びN,N−ジ−C1〜C4アルキルカルバモイル から選択される1又は2個の置換基を有し、かつBの置換基中の全てのフェニル 基は場合により、ハロ、トリフルオロメチル、シアノ、C1〜C4アルキル、C2 〜C4アルケニル、C2〜C4アルキニル、C1〜C4アルコキシ、C2〜C4アルケ ニルオキシ及びC2〜C4アルキニルオキシから選択される1又は2個の置換基を 有し, T1はCH又はNであり; T2はCH又はNであり; 但し、T1及びT2の少なくとも一方はNであり、その際、T1、T2、L1、R2及 びR3により形成される複素環は場合によりヒドロキシ、オキソ、カルボ キシ及びC1〜C4アルコキシカルボニルから選択される1個又は2個の置換基又 は次の基: −(CH2)n−R、−(CH2)n−NRR1、−CO−R、−CO−NRR1、− (CH2)n−CO−R及び−(CH2)n−CO−NRR1の1個の置換基により 置換されており その際、nは0、1又は2、有利にnは1又は2を表し; R及びR1は無関係に、水素、C1〜C4アルキル、C2〜C4アルケニル、C2〜C4 アルキニル、ヒドロキシC1〜C4アルキル、カルボキシC1〜C4アルキル及び C1〜C4アルコキシカルボニルC1〜C4アルキルから選択され、又は可能なR及 びR1は一緒になって5又は6員の場合により置換された飽和又は部分的に不飽 和(有利に飽和)の複素環を形成することができ、この複素環はR及びR1が結 合する窒素原子に対して付加的に窒素、酸素及び硫黄から選択される1又は2個 のヘテロ原子を有することができ、 T1がCH又はNである場合、X1はSO、SO2、C(R4)2又はCOを表すか ;又はT1がCHである場合、付加的にX1はO又はSを表し; 及び各R4は無関係に水素又はC1〜C4アルキルを表し; L1はC1〜C4アルキレン又はC1〜C3アルキレン カルボニルを表し; R2は水素又はC1〜C4アルキルを表し; R3は水素又はC1〜C4アルキルを表し; 又はR2及びR3は一緒になってC1〜C4アルキレン又は−CH2CO−基を形成 し;その際、T1、R2、R3、T2及びL1により形成された環は、場合により置 換されており、但し、T1及びT2が両方ともNである場合には、L1はメチレン ではなく、かつR2及びR3も一緒になってメチレンを表さないものとし; X2はS(O)y(その際yは1又は2を表す)、C(R5)2又はCOを表し;及 び各R5は水素又はC1〜C4アルキルを表し; Qはフェニル、ナフチル、フェニルC1〜C4アルキル、フェニルC2〜C4アルケ ニル、フェニルC2〜C4アルキニル、又は窒素、酸素及び硫黄から選択される4 個までのヘテロ原子を含有する複素環式基を表し、及びQは場合により、ハロ、 トリフルオロメチル、トリフルオロメトキシ、シアノ、ヒドロキシ、アミノ、ニ トロ、トリフルオロメチルスルホニル、カルボキシ、カルバモイル、C1〜C4ア ルキル、C2〜C4アルケニル、C2〜C4アルキニル、C1〜C4アルコキシ、C2 〜C4アルケニルオキシ、C2〜C4アルキニルオキシ、C1〜C4アルキルチオ、 C1〜C4アルキルスルフィニル、C1〜C4アルキル スルホニル、C1〜C4アルキルアミノ、ジ−C1〜C4アルキルアミノ、C1〜C4 アルコキシカルボニル、N−C1〜C4アルキルカルバモイル、N,N−ジ−C1 〜C4アルキルカルバモイル、C2〜C4アルカノイル、C2〜C4アルカノイルア ミノ、ヒドロキシC1〜C4アルキル、C1〜C4アルコキシC1〜C4アルキル、カ ルボキシC1〜C4アルキル、C1〜C4アルコキシカルボニルC1〜C4アルキル、 カルバモイルC1〜C4アルキル、N−C1〜C4アルキルカルバモイルC1〜C4ア ルキル、N,N−ジ−C1〜C4アルキルカルバモイルC1〜C4アルキル、フェニ ル、ヘテロアリール、フェノキシ、フェニルチオ、フェニルスルフィニル、フェ ニルスルホニル、ベンジル、ベンゾイル、ヘテロアリールオキシ、ヘテロアリー ルチオ、ヘテロアリールスルフィニル及びヘテロアリールスルホニルから選択さ れる1、2又は3個の置換基により置換されており、その際、前記ヘテロアリー ル置換基又はヘテロアリール含有置換基中のヘテロアリール基は、窒素、酸素及 び硫黄から選択される3個までのヘテロ原子を含有する5又は6員の単環式ヘテ ロアリール環であり、その際、前記フェニル、ヘテロアリール、フェノキシ、フ ェニルチオ、フェニルスルフィニル、フェニルスルホニル、ヘテロアリールオキ シ、ヘテロアリールチオ、ヘテロアリールスルフィニル、ヘテロアリールスル ホニル、ベンジル又はベンゾイル置換基は場合により、ハロ、トリフルオロメチ ル、シアノ、ヒドロキシ、アミノ、ニトロ、カルボキシ、カルバモイル、C1〜 C4アルキル、C1〜C4アルコキシ、C1〜C4アルキルアミノ、ジ−C1〜C4ア ルキルアミノ、C1〜C4アルコキシカルボニル、N−C1〜C4アルキルカルバモ イル、N,N−ジ−C1〜C4アルキルカルバモイル及びC2〜C4アルカノイルア ミノから選択される1、2又は3個の置換基を有する]で示される化合物及びそ の調剤学的に認容性の塩。 2. Aがピリジル、ピリミジニル又はピリダジニル環である、請求項1記載の 式(I)の化合物。 3. Aが4−ピリミジニル又は4−ピリジルである、請求項2記載の式(I) の化合物。 4. Bがパラフェニレンである、請求項1から3までのいずれか1項記載の式 (I)の化合物。 5. T1、R2、R3、T2及びLにより形成される環が1,4−ピペラジンジイ ルである、請求項1から4までのいずれか1項記載の式(I)の化合物。 6. X1がCOである、請求項1から5までのいずれか1項記載の式(I)の 化合物。 7. X2がSO2である、請求項1から6までのいずれか1項記載の式(I)の 化合物。 8. Aがピリジル、ピリミジニル又はピリダジニルを表し; Bはパラフェニレンを表し; X1はCO、SO2又はCH2を表し; T1及びT2は両方ともNを表し; L1はエチレン又はプロピレンを表し; R2及びR3は結合してエチレン基又はプロピレン基又はメチレンカルボニル基 を形成し; X2はSO2を表し; Qは場合によりフルオロ、クロロ又はブロモで置換されたスチリル又はナフチ ルを表すか、場合によりフルオロフェニル、クロロフェニル又はブロモフェニル で置換されたフェニルを表す、 請求項1記載の式(I)の化合物及びその調剤学的に認容性の塩。 9. 1−(6−ブロモナフト−2−イルスルホニル)−4−[4−(4−ピリ ミジニル)ベンゾイル] ペラジン;1−(6−クロロナフト−2−イルスルホ ニル)−4−[4−(4−ピリジル)ベンゾイル]ピペラジン;1−(6−ブロ モナフト−2−イルスルホニル)−4−[4−(4−ピラダジニル)ベンゾイル ]ピペラジンから選択される式(I)の化合物及びその調剤学的に認容性の塩。 10. 医学的治療に使用するための、請求項1から9までのいずれか1項記載 の式(I)の化合物。 11. 請求項1から9までのいずれか1項記載の式(I)の化合物及び調剤学 的に認容性の希釈剤又は 担持剤を含有する調剤学的調製剤。 12. ファクターXa阻害作用を作り出す際に使用するための医薬品の製造に おける、請求項1から9までのいずれか1項記載の式(I)の化合物の使用。 13. 請求項1から9までのいずれか1項記載の式(I)の化合物の調剤学的 有効量を患者に投与することよりなる、ファクターXaが媒介する疾患又は医学 的症状の予防又は治療方法。 14. 請求項1記載の式(I)の化合物の製造方法において、 (a) T1がNであり、X1がCOである式(I)の化合物の製造のために、 有利に、適当な塩基の存在で、式(II): HN(R2)−L1−T2(R3)−X2−Q (II) のアミンを、式(III): A−B−COOH(III) の酸又はその反応性誘導体と反応させるか、 (b) T1がCHであり、X1がOである式(I)の化合物の製造のために、 有利に、適当なカプリング剤の存在で、式(IV) Z−CH(R2)−L1−T2(R3)−X2−Q (IV) [式中、Zは脱離可能基を表す]の化合物を、式(V): A−B−OH(V) のフェノール性化合物と反応させるか、 (c) T1はNであり、X1はCH(R4)である式(I)の化合物の製造にた めに、式(VI): A−B−CO−R4 (VI) [式中、R4は水素又はC1〜C4アルキルを表す]のケト化合物を、前記の式( II)のアミンで還元アミノ化するか、 (d) 式(VII): Z−B−X1−T1(R2)−L1−T2(R3)−X2−Q (VII) [式中、Zは脱離可能基を表す]の化合物を、環Aの活性化誘導体と反応させる か、 (e) 式(VII)[式中、Zは環化可能な官能基を表す]の化合物にA環を 形成させるか、 (f) T2はNを表す化合物の製造のために、式(VIII): A−B−X1−T1(R2)−L1−NH(R3) (VIII) の化合物を、式(IX): Z−X2−Q (IX) の化合物と反応させるか、 (g) T1はNであり、X1はSO又はSO2である化合物の製造のために、前 記の式(II)の化合物を式(X): A−B−SOx−Z (X) [式中、xは1又は2であり、Zは脱離可能基を表す]の化合物と反応させるか 、 (h) 式(I)の化合物の製造のために、T2とQとをカプリングさせて−T2 −X2−Q基を製造し、B−X1−T1の製造のために方法(a)、(c)及び( g)に記載されたと同様の方法を使用するが、 (i) X1が式SO、SO2を表し、BはC1〜C4アルキルスルフィニル、C1 〜C4アルキルスルホニル、1−オキソチオモルホリノ又は1,1−ジオキソチ オモルホリノ基を有し、X2は式SO又はSO2の基を表し、QはC1〜C4アルキ ルスルフィニル、C1〜C4アルキルスルホニル、フェニルスルフィニル、フェニ ルスルホニル、ヘテロアリールスルフィニル又はヘテロアリールスルホニル基を 有する式(I)の化合物の製造のために、X1がチオ基を表す式(I)の相応す る化合物を酸化する、 請求項1記載の式(I)の化合物の製造方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9623283.0A GB9623283D0 (en) | 1996-11-08 | 1996-11-08 | Heterocyclic derivatives |
GB9623283.0 | 1996-11-08 | ||
GB9715893.5 | 1997-07-29 | ||
GBGB9715893.5A GB9715893D0 (en) | 1997-07-29 | 1997-07-29 | Heterocyclic derivatives |
PCT/GB1997/003033 WO1998021188A1 (en) | 1996-11-08 | 1997-11-04 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504113A true JP2001504113A (ja) | 2001-03-27 |
JP2001504113A5 JP2001504113A5 (ja) | 2006-01-05 |
Family
ID=26310361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52227498A Ceased JP2001504113A (ja) | 1996-11-08 | 1997-11-04 | ファクターXaを阻害する複素環式化合物誘導体 |
Country Status (28)
Country | Link |
---|---|
US (2) | US6300330B1 (ja) |
EP (2) | EP0937048B1 (ja) |
JP (1) | JP2001504113A (ja) |
KR (1) | KR20000053128A (ja) |
CN (1) | CN1220682C (ja) |
AT (1) | ATE258167T1 (ja) |
AU (1) | AU731929B2 (ja) |
BG (1) | BG64258B1 (ja) |
BR (1) | BR9712672A (ja) |
CA (1) | CA2266890A1 (ja) |
CZ (1) | CZ296342B6 (ja) |
DE (1) | DE69727308T2 (ja) |
DK (1) | DK0937048T3 (ja) |
ES (1) | ES2213208T3 (ja) |
HU (1) | HUP0001098A3 (ja) |
IL (1) | IL129706A (ja) |
MY (1) | MY124122A (ja) |
NO (1) | NO312894B1 (ja) |
NZ (1) | NZ334710A (ja) |
PL (1) | PL189703B1 (ja) |
PT (1) | PT937048E (ja) |
RU (2) | RU2213732C2 (ja) |
SK (1) | SK284665B6 (ja) |
TR (1) | TR199901006T2 (ja) |
TW (1) | TW458968B (ja) |
UA (1) | UA56197C2 (ja) |
WO (1) | WO1998021188A1 (ja) |
YU (1) | YU20999A (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007238447A (ja) * | 2006-03-03 | 2007-09-20 | Ne Chemcat Corp | 炭素−炭素結合の生成方法 |
JP2008531592A (ja) * | 2005-02-24 | 2008-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムイオンチャンネル開口薬としての新規なピリジン誘導体 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
WO1997028128A1 (en) | 1996-02-02 | 1997-08-07 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
WO1998035959A1 (en) | 1997-02-13 | 1998-08-20 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
AU5999698A (en) | 1997-02-13 | 1998-09-08 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
WO1998054164A1 (en) | 1997-05-30 | 1998-12-03 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
ES2255733T3 (es) | 1997-09-30 | 2006-07-01 | Daiichi Pharmaceutical Co., Ltd. | Derivados sulfonilo. |
ZA99607B (en) * | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
AU2298899A (en) | 1998-02-05 | 1999-08-23 | Takeda Chemical Industries Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
GB9809349D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Heterocyclic derivatives |
PT1082321E (pt) * | 1998-05-02 | 2005-03-31 | Astrazeneca Ab | Derivados heterociclicos que inibem o factor xa |
GB9809350D0 (en) * | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Novel salt |
US6747023B1 (en) * | 1998-08-11 | 2004-06-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
CA2348740A1 (en) | 1998-12-23 | 2000-07-06 | Ruth R. Wexler | Thrombin or factor xa inhibitors |
GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
TW200404789A (en) | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
GB9914342D0 (en) * | 1999-06-19 | 1999-08-18 | Zeneca Ltd | Compound |
DE60027718T2 (de) | 1999-06-22 | 2007-05-16 | Takeda Pharmaceutical Co. Ltd. | Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung |
GB9917344D0 (en) * | 1999-07-24 | 1999-09-22 | Zeneca Ltd | Novel salt |
DE60041584D1 (de) * | 1999-07-28 | 2009-04-02 | Aventis Pharma Inc | Substituierte oxoazaheterozyclische verbindungen |
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
GB0012448D0 (en) | 2000-05-24 | 2000-07-12 | Astrazeneca Ab | New process |
EP1322643A1 (en) * | 2000-09-29 | 2003-07-02 | Millennium Pharmaceuticals, Inc. | Piperazin-2-one amides as inhibitors of factor xa |
WO2002036584A1 (en) | 2000-11-02 | 2002-05-10 | F. Hoffmann-La Roche Ag | Cholesterol lowering benzo`b! thiophenes and benzo`d! isothiazoles |
JP2004523506A (ja) | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
US7365205B2 (en) * | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
EP1430068A1 (en) | 2001-09-17 | 2004-06-23 | Ortho-Mcneil Pharmaceutical, Inc. | 6-o-carbamate-11,12-lacto-ketolide antimicrobials |
KR20050044497A (ko) | 2001-11-14 | 2005-05-12 | 아벤티스 파마슈티칼스 인크. | 올리고펩티드 및 카텝신 s 억제제로서 이를 포함하는조성물 |
RU2004117082A (ru) | 2001-12-05 | 2005-04-10 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Кетолидные 6-0-ацил-производные эритромицина в качестве антибактериальных средств |
CN1703395A (zh) * | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
WO2004058715A1 (ja) * | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | ジアミン誘導体 |
US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
WO2007008145A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
AU2020300002A1 (en) | 2019-07-01 | 2022-02-24 | Tonix Pharma Limited | Anti-CD154 antibodies and uses thereof |
JP2024503625A (ja) | 2021-01-06 | 2024-01-26 | トニックス ファーマ リミテッド | 改変された抗cd154抗体により免疫寛容を誘導する方法 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4167567A (en) | 1978-05-05 | 1979-09-11 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
SE8203887D0 (sv) | 1982-06-23 | 1982-06-23 | Kabivitrum Ab | Nya trombininhiberande foreningar |
DE3246932A1 (de) | 1982-12-16 | 1984-06-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | Substituierte 5h-pyrimido(5,4-b)indole |
FR2557570B1 (fr) | 1984-01-04 | 1986-04-18 | Adir | Nouveaux derives de la quinoleine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
US4840963A (en) | 1984-03-14 | 1989-06-20 | Merck & Co., Inc. | 2-Sulfamoyl-1H-indole derivatives for the treatment of elevated intraocular pressure |
GB8601160D0 (en) | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
GB8603120D0 (en) | 1986-02-07 | 1986-03-12 | Pfizer Ltd | Anti-dysrhythmia agents |
GB8609630D0 (en) | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
GB8710494D0 (en) | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Antiarrhythmic agents |
JPH0696575B2 (ja) | 1987-09-17 | 1994-11-30 | 三菱化成株式会社 | 4−アミノピリジン誘導体及びその酸付加塩 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
GB8817315D0 (en) | 1988-07-20 | 1988-08-24 | Pfizer Ltd | Triazole antifungal agents |
GB8819307D0 (en) | 1988-08-13 | 1988-09-14 | Pfizer Ltd | Antiarrhythmic agents |
DE3905364A1 (de) | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
IL94805A (en) * | 1989-06-28 | 1994-04-12 | Ciba Geigy Ag | Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them |
IE64358B1 (en) | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
US5032604A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
DE3943225A1 (de) | 1989-12-23 | 1991-06-27 | Schering Ag | Neue ss-carboline, verfahren zu deren herstellung und deren verwendung in arzneimitteln |
KR920703558A (ko) | 1990-11-15 | 1992-12-18 | 원본미기재 | 메타-치환 페닐알라닌 유도체 |
DE4036552C1 (ja) | 1990-11-16 | 1992-02-06 | Boehringer Mannheim Gmbh, 6800 Mannheim, De | |
EP0495750A3 (en) | 1991-01-14 | 1992-09-16 | Ciba-Geigy Ag | Heterocyclic hydroxylamine |
IT1245712B (it) | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
FR2676054B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
WO1993000342A1 (en) | 1991-06-21 | 1993-01-07 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
WO1993006085A1 (en) | 1991-09-19 | 1993-04-01 | Smithkline Beecham Corporation | Pyridine compounds for treating leukotriene-related diseases |
PH31294A (en) | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
HU211995B (en) | 1992-06-30 | 1996-01-29 | Gyogyszerkutato Intezet | Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them |
US5371091A (en) | 1992-08-31 | 1994-12-06 | Bristol-Myers Squibb Company | Heteroaromatic amine thrombin inhibitors |
FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5332822A (en) | 1992-12-24 | 1994-07-26 | Bristol-Myers Squibb Company | Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors |
US5364865A (en) | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
WO1994018185A1 (de) | 1993-02-10 | 1994-08-18 | Pentapharm Ag | Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren |
TW257757B (ja) | 1993-03-03 | 1995-09-21 | Boehringer Mannheim Gmbh | |
DE4306506A1 (de) | 1993-03-03 | 1994-09-08 | Boehringer Mannheim Gmbh | Neue 4-Alkylaminopyridine - Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
DE4306873A1 (de) | 1993-03-05 | 1994-09-08 | Boehringer Mannheim Gmbh | Neue 4-Aminopyridine-Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
ZW4194A1 (en) | 1993-03-29 | 1994-12-21 | Zeneca Ltd | Heterocyclic compounds |
PT825184E (pt) | 1993-03-29 | 2001-11-30 | Astrazeneca Ab | Derivados heterociclicos como inibidores de agregacao de plaquetas |
US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
AU3107795A (en) | 1994-08-09 | 1996-03-07 | Pentapharm Ag | Inhibitors of the benzamidine type |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
WO1996019223A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
WO1996019475A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
IT1282797B1 (it) | 1995-04-21 | 1998-03-31 | Colla Paolo | Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
WO1997028128A1 (en) | 1996-02-02 | 1997-08-07 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
GB9602294D0 (en) | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
CA2244851A1 (en) * | 1996-02-22 | 1997-08-28 | Petrus Fredericus Wilhelmus Stouten | M-amidino phenyl analogs as factor xa inhibitors |
ATE230399T1 (de) | 1996-08-14 | 2003-01-15 | Astrazeneca Ab | Substituierte pyrimidinderivate und ihre pharmazeutische anwendung |
UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
-
1997
- 1997-04-11 UA UA99063121A patent/UA56197C2/uk unknown
- 1997-11-04 DK DK97911333T patent/DK0937048T3/da active
- 1997-11-04 WO PCT/GB1997/003033 patent/WO1998021188A1/en active IP Right Grant
- 1997-11-04 AT AT97911333T patent/ATE258167T1/de not_active IP Right Cessation
- 1997-11-04 DE DE69727308T patent/DE69727308T2/de not_active Expired - Lifetime
- 1997-11-04 HU HU0001098A patent/HUP0001098A3/hu unknown
- 1997-11-04 SK SK613-99A patent/SK284665B6/sk unknown
- 1997-11-04 PT PT97911333T patent/PT937048E/pt unknown
- 1997-11-04 KR KR1019990704055A patent/KR20000053128A/ko active Search and Examination
- 1997-11-04 CN CNB971994269A patent/CN1220682C/zh not_active Expired - Fee Related
- 1997-11-04 IL IL12970697A patent/IL129706A/en not_active IP Right Cessation
- 1997-11-04 RU RU99112135/04A patent/RU2213732C2/ru not_active IP Right Cessation
- 1997-11-04 ES ES97911333T patent/ES2213208T3/es not_active Expired - Lifetime
- 1997-11-04 CA CA002266890A patent/CA2266890A1/en not_active Abandoned
- 1997-11-04 JP JP52227498A patent/JP2001504113A/ja not_active Ceased
- 1997-11-04 PL PL97333241A patent/PL189703B1/pl not_active IP Right Cessation
- 1997-11-04 NZ NZ334710A patent/NZ334710A/xx unknown
- 1997-11-04 US US09/297,768 patent/US6300330B1/en not_active Expired - Fee Related
- 1997-11-04 BR BR9712672-1A patent/BR9712672A/pt not_active Application Discontinuation
- 1997-11-04 CZ CZ0163499A patent/CZ296342B6/cs not_active IP Right Cessation
- 1997-11-04 EP EP97911333A patent/EP0937048B1/en not_active Expired - Lifetime
- 1997-11-04 TR TR1999/01006T patent/TR199901006T2/xx unknown
- 1997-11-04 EP EP03011815A patent/EP1358909A1/en not_active Withdrawn
- 1997-11-04 YU YU20999A patent/YU20999A/sh unknown
- 1997-11-04 AU AU48748/97A patent/AU731929B2/en not_active Ceased
- 1997-11-05 TW TW086116467A patent/TW458968B/zh not_active IP Right Cessation
- 1997-11-06 MY MYPI97005268A patent/MY124122A/en unknown
-
1999
- 1999-05-07 NO NO19992230A patent/NO312894B1/no unknown
- 1999-05-25 BG BG103430A patent/BG64258B1/bg unknown
-
2001
- 2001-09-27 US US09/963,686 patent/US6936610B2/en not_active Expired - Fee Related
-
2003
- 2003-05-21 RU RU2003115094/04A patent/RU2003115094A/ru not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531592A (ja) * | 2005-02-24 | 2008-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムイオンチャンネル開口薬としての新規なピリジン誘導体 |
JP2007238447A (ja) * | 2006-03-03 | 2007-09-20 | Ne Chemcat Corp | 炭素−炭素結合の生成方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504113A (ja) | ファクターXaを阻害する複素環式化合物誘導体 | |
US6022869A (en) | Aminoheterocyclic compounds with antithrombotic/anticoagulant effect | |
US6458793B1 (en) | Heterocyclic derivatives which inhibit factor Xa | |
CN102918034A (zh) | 多取代芳族化合物作为凝血酶的抑制剂 | |
SK38597A3 (en) | Aminoheterocyclic derivatives, process for producing them, a pharmaceutical composition containing them and their use | |
JP2002513790A (ja) | Xa因子を阻害する複素環誘導体 | |
US6486154B1 (en) | (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors | |
JP2002513782A (ja) | Xa因子を阻害する複素環誘導体 | |
JP2002536443A (ja) | 第Xa因子阻害剤としてのヘテロ環式誘導体 | |
MXPA99003712A (en) | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | |
MXPA00000505A (en) | Heterocyclic derivatives which inhibit factor xa | |
MXPA01008067A (es) | Derivados heterociclicos como inhibidores del factor xa | |
CZ2000293A3 (cs) | Heterocyklické deriváty, které inhibují faktor Xa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20031212 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20031216 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081014 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |